Doctor Plant Debut Dendrobium Oligosaccharide at CAME
Doctor Plant launched its Dendrobium oligosaccharide at the 2026 CAME Expo. The ingredient has been registered with NMPA. Its patent enzyme technology promotes collagen synthesis, offering a sample of independent R&D for local brands.
New Launch and Expo Updates
On September 17, the 2026 CAME Expo opened in Nanjing. Doctor Plant featured high-altitude plants at its booth and launched the Dendrobium Time Repair Oil Bead Mask. The new product features Dendrobium oligosaccharide, targeting post-medical aesthetics repair and labeled for sensitive skin. The accompanying repair essential oil was already on the market. A round-table forum discussed the industrialization of raw materials.
Four-Stage Iteration and Tech Breakthrough
Doctor Plant built a joint R&D center with the Kunming Institute of Botany in 2014. After over ten years and thousands of experiments, the R&D path evolved from Dendrobium extract to oligosaccharide. The core breakthrough is a patented enzyme technology that cuts large polysaccharides into small oligosaccharides. In vitro cell data shows it promotes Type I collagen synthesis 2.46 times more than Pro-Xylane and 3.20 times more than Retinol.
In terms of IP rights, related patents were authorized by the European Patent Office in August 2025. As of now, the company holds 223 patents, including 68 invention patents. In May 2026, Dendrobium officinale oligosaccharide completed NMPA new raw material registration under No. 20260074. Previously, D. chrysotoxum and Tuber sinensis extracts were also registered. The company now possesses three in-house new raw materials.
Industry Data and Context
NMPA data indicates 169 new cosmetic raw material registrations in 2025. Plant extracts accounted for 35%, the highest share. With increased registrations, ingredient concept homogenization has intensified. Ingredients that reach the molecular level, explain mechanisms, and secure global patents remain scarce. High-end active ingredients are long dominated by international companies.
Implications for B2B Procurement
Doctor Plant's path shows brands must extend to upstream R&D to build competitiveness. Buyers should focus on mechanism research and patent barriers when selecting materials. Brands seeking long-term moats need exclusive ingredients to avoid homogenization. Industry-academia collaboration shortens the timeline from lab to shelf, enhancing traceability and compliance safety.
Source:青眼情报
Note: compiled and rewritten by BIOSPHERE editors from public reporting; illustration AI-generated. See the source for full details.